News >

Frontline Durvalumab/Tremelimumab Misses OS Endpoint in Metastatic NSCLC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Aug 21, 2019

Jose Baselga, MD, PhD, executive vice president, Oncology R&D, AstraZenec

José Baselga, MD, PhD

The combination of durvalumab (Imfinzi) and tremelimumab did not improve overall survival (OS) compared with standard platinum-based chemotherapy in previously untreated patients with stage IV metastatic non–small cell lung cancer (NSCLC) who have tumor mutational burden (TMB) ≥20 mutations/megabase (mut/mB), missing the primary endpoint of the phase III NEPTUNE trial (NCT02542293).1

 

References

  1. Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in stage IV non-small cell lung cancer. AstraZeneca. Published August 21, 2019. https://bit.ly/2TPGs2Y. Accessed August 21, 2019.
  2. Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. Ann Oncol. 2018;29(10). doi: 10.1093/annonc/mdy511.005.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x